In a report released yesterday, Liana Moussatos from Wedbush reiterated a Buy rating on Pacira Pharmaceuticals (PCRX), with a price target of $85. The company’s shares closed yesterday at $45.60.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -6.1% and a 38.4% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pacira Pharmaceuticals with a $53.22 average price target, implying a 16.7% upside from current levels. In a report issued on May 2, Piper Jaffray also maintained a Buy rating on the stock with a $57 price target.
See today’s analyst top recommended stocks >>
Based on Pacira Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $2.77 million. In comparison, last year the company had a GAAP net loss of $10.68 million.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PCRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Biosciences, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.
